Article info
PDFResearch ethics
Brief Report
Diagnostic misconceptions? A closer look at clinical research on Alzheimer's disease
- Correspondence to Lara Katharina Kutschenko, Institute for History, Philosophy and Ethics of Medicine, University Medical Center Mainz, Am Pulverturm 13, 55131 Mainz, Germany; kutschel{at}uni-mainz.de
Citation
Diagnostic misconceptions? A closer look at clinical research on Alzheimer's disease
Publication history
- Received June 2, 2011
- Revised June 13, 2011
- Accepted June 15, 2011
- First published August 25, 2011.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist
- Retinal imaging in Alzheimer’s disease
- On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Amyloid PET imaging in clinical practice
- Mild cognitive impairment in primary care: a clinical review
- Imaging of neuroinflammation in dementia: a review
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia
- Pupillary light reaction in preclinical Alzheimer’s disease subjects compared with normal ageing controls
- Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults